Inclusion Criteria:

          -  Since p53 mutations occur in a wide variety of tumor types, this is a mixed histology
             study for incurable tumors; subjects with the following solid tumors are eligible for
             screening: non-small cell lung cancer, squamous cell carcinoma of the head and neck,
             hepatocellular carcinoma, renal cell carcinoma, melanoma, bladder, soft tissue
             sarcoma, triple-negative breast cancer, and colorectal carcinoma displaying
             microsatellite instability and pancreatic cancer

          -  Advanced (unresectable) solid tumors: patients must have failed or been intolerant to
             at least one line of standard therapy or refuse standard treatment

          -  Performance status: patients must have an Eastern Cooperative Oncology Group (ECOG) =<
             2 (Karnofsky >= 60%)

          -  Informed consent: all subjects must have the ability to understand and the willingness
             to sign an Institutional Review Board (IRB) approved consent form

          -  Absolute neutrophil count: >= 1,500/ul

          -  Platelets >= 100,000/ul

          -  Hemoglobin level: must be greater than 9 g/dL

          -  Renal function: calculated or measured creatinine clearance >= 50 ml/min and/or serum
             creatinine =< 1.6 mg/dl

          -  Total bilirubin =< 1.5 x institutional upper limit of normal

          -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 times
             institutional upper normal level (AST and ALT =< 5 times institutional upper normal
             level, if there is evidence of liver metastasis)

          -  Confirmed p53 involvement: patients with p53 over-expression by immunohistochemistry
             (>= 10% of cells within the tumor staining positive) or those with a p53 mutation as
             determined by mutational analysis of tumor tissue will be eligible; patients with
             prior exposure to p53-based vaccines will be eligible

          -  Agreement to use adequate contraception: women of child-bearing potential must use
             contraception prior to study entry and for six months after study participation; men
             that are sexually active whose partners are women of childbearing age must use condoms

        Exclusion Criteria:

          -  Patients may not be receiving any additional investigational agents or radiation
             therapy

          -  Pregnancy: pregnant women are excluded from this study; should a woman become pregnant
             or suspect that she is pregnant while participating on the trial, she should inform
             her treating physician immediately; women who are pregnant or breastfeeding are
             excluded

          -  Patients with known brain metastasis

          -  Radiotherapy within 4 weeks prior to entering the study

          -  Patients with previous exposure to anti-programmed cell death (PD)-1 or
             anti-programmed cell death ligand 1 (PDL-1) will not be eligible

          -  History of allergy to egg proteins

          -  Patients who have not recovered from adverse events due to agents administered more
             than 4 weeks earlier

          -  Concurrent use of systemic corticosteroids (nasal corticosteroids, inhaled steroids,
             adrenal replacement steroids, and topical steroids are allowed)

          -  History of immunodeficiency or autoimmune disease: patients with a history of
             immunodeficiency, including organ grafts and human immunodeficiency virus (HIV), will
             not be eligible

          -  Patients with a history of autoimmune disease will also be excluded, specifically
             those with any active autoimmune disease or a condition that requires systemic
             corticosteroids; exceptions to this are subjects with vitiligo and type I diabetes
             mellitus, who will be permitted to enroll

          -  Patients with a history of severe immune-mediated adverse reactions with ipilimumab:
             this will be defined as any grade 4 toxicity requiring treatment with corticosteroids
             (greater than 10 mg/day prednisone or equivalent dose) for greater than 12 weeks

          -  Patients with a history of cardiac disease are excluded; baseline electrocardiography
             and assessment of serum troponin (I) are included the screening exams; subjects in
             whom these assays are abnormal (electrocardiogram [EKG] excluding 1st degree bundle
             branch block, sinus bradycardia, sinus tachycardia or non-specific T wave changes,
             serum troponin >= grade 2) are ineligible

          -  Non-compliance: if it is the opinion of the investigator that a subject may be unable
             to comply with the safety monitoring requirements of the study, they will be excluded